| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18305 R77084 |
Laspro, 2024 | Oral clefts (ICD 10 codes Q35 or Q36 or Q37) | during pregnancy (anytime or not specified) excluded | nested case control | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified |
1.25 [1.16;1.34] excluded (exposition period) |
751/- 11,347/- | 12,098 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7468 R22179 |
Anderson, 2020 | Any oral cleft | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 0.78 [0.55;1.11] | -/- 0/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8217 R25647 |
Jordan, 2016 | Oro‐facial clefts | 3 months or more before pregnancy or1st trimester excluded | retrospective cohort (registry) | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified |
1.74 [0.65;4.64] excluded (exposition period) |
4/1,374 861/506,155 | 865 | 1,374 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5888 R14769 |
Ban (Controls unexposed, disease free), 2014 | Orofacialcleft | 1st trimester | retrospective cohort (claims database) | unexposed, disease free | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.99 [0.14;6.96] | -/757 438/325,294 | - | 757 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6018 R15585 |
Jimenez-Solem (Controls unexposed, NOS), 2012 | Oro-facial clefts | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.88 [0.12;6.24] | 1/817 -/843,797 | - | 817 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 0.79 [0.56;1.11] | 0 | 1,574 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, disease free; 2: Controls unexposed, NOS;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded